Magnus Life

Magnus Life Science is a life sciences company based in London that operates through a unique 'hub and spoke' model to accelerate the development of clinical-stage assets originating from University College London (UCL). The company manages a diverse portfolio of programs organized into distinct business units, including Magnus Oxygen, Magnus Growth, and Magnus Flow, each focusing on specific therapeutic areas such as fetal medicine, cardiology, and oncology. Its lead programs include a gene therapy for fetal growth restriction and a novel treatment for reperfusion injury in heart attack patients. By leveraging deep academic ties and a centralized management team, Magnus Life Science aims to bridge the gap between early-stage academic research and commercial clinical development.